1. Home
  2. SILO vs LCFY Comparison

SILO vs LCFY Comparison

Compare SILO & LCFY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SILO
  • LCFY
  • Stock Information
  • Founded
  • SILO 2010
  • LCFY 2009
  • Country
  • SILO United States
  • LCFY Australia
  • Employees
  • SILO N/A
  • LCFY N/A
  • Industry
  • SILO Apparel
  • LCFY
  • Sector
  • SILO Consumer Discretionary
  • LCFY
  • Exchange
  • SILO Nasdaq
  • LCFY Nasdaq
  • Market Cap
  • SILO 5.9M
  • LCFY 5.9M
  • IPO Year
  • SILO N/A
  • LCFY 2022
  • Fundamental
  • Price
  • SILO $0.70
  • LCFY $6.32
  • Analyst Decision
  • SILO
  • LCFY
  • Analyst Count
  • SILO 0
  • LCFY 0
  • Target Price
  • SILO N/A
  • LCFY N/A
  • AVG Volume (30 Days)
  • SILO 948.9K
  • LCFY 1.6M
  • Earning Date
  • SILO 11-11-2025
  • LCFY 11-11-2025
  • Dividend Yield
  • SILO N/A
  • LCFY N/A
  • EPS Growth
  • SILO N/A
  • LCFY N/A
  • EPS
  • SILO N/A
  • LCFY N/A
  • Revenue
  • SILO $72,102.00
  • LCFY $2,231,313.00
  • Revenue This Year
  • SILO $1.86
  • LCFY N/A
  • Revenue Next Year
  • SILO N/A
  • LCFY N/A
  • P/E Ratio
  • SILO N/A
  • LCFY N/A
  • Revenue Growth
  • SILO N/A
  • LCFY N/A
  • 52 Week Low
  • SILO $0.41
  • LCFY $2.51
  • 52 Week High
  • SILO $3.37
  • LCFY $13.98
  • Technical
  • Relative Strength Index (RSI)
  • SILO 53.25
  • LCFY 61.50
  • Support Level
  • SILO $0.58
  • LCFY $5.95
  • Resistance Level
  • SILO $0.83
  • LCFY $7.60
  • Average True Range (ATR)
  • SILO 0.05
  • LCFY 0.78
  • MACD
  • SILO 0.01
  • LCFY 0.11
  • Stochastic Oscillator
  • SILO 45.56
  • LCFY 67.43

About SILO Silo Pharma Inc.

SILO Pharma Inc is a developmental stage biopharmaceutical company developing novel therapeutics that address underserved conditions including stress-induced psychiatric disorders, chronic pain conditions, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in novel formulations and drug delivery systems. The company's primary program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders.

About LCFY Locafy Limited

Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.

Share on Social Networks: